Key facts
- Notable investors include AIR Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for CellRep
- ·The full record, as it builds
Funding rounds
No funding rounds for CellRep are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CellRep
Developer of cell reprogramming strategies intended to increase the functionality of immune cells. The company offers artificial intelligence-driven target identification, single-cell level biomarker screening, in vitro compound testing, and in vivo preclinical validation using dynamic cell reprogramming without genetic editing, enabling cell therapy developers to improve therapeutic efficacy, reduce manufacturing complexity, and achieve more scalable personalized treatments.
- Sector
- Healthcare
- HQ
- Dover, DE, United States
- Founded
- 2012
- Employees
- 8
- Website
- cellrep.bio/
- Ownership
- Privately Held (backing)
CellRep doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CellRep shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CellRep in its N-PORT filings yet. We sweep new filings monthly.